{8 (Phenothiazinyl)propyl{9 -piperidyl-benzimidazolinones

ABSTRACT

Compounds of the class of 1-(1-(3-(10-phenothiazinyl)-propyl)-4piperidyl)-2-benzimidazolinones, useful as neuroleptic agents.

United States Patent [191 Soudijn et al.

[ Mar. 25, 1975 Adriaan Jan Janssen, Vosselaar, all of Belgium [73] Assignee: Janssen Pharmaceutical, N.V.,

Beerse, Belgium [22] Filed: Dec. 28, 1973 [21] Appl. No.: 429,245

Related US. Application Data [63] Continuation-impart of Ser. No. 333,855, Feb. 20,

1973, abandoned.

[52] US. Cl. 260/243 A, 424/247, 260/293.6

[51] Int. Cl C07d 93/14 [58] Field 0f Search 260/243 A, 293.6

[56] References Cited UNITED STATES PATENTS 3,359,265 12/1967 Jucker et al. 260/243 A 3,574,204 4/1971 Nakanishi et al. 260/243 A 3,654,270 4/1972 Umemoto et al. 260/243 A 3,818,017 6/1974 Janssen et al 260/293.6

Primary Examiner.lohn D. Randolph Attorney, Agent, or FirmSal vatore R. Come 5? ABSTRACT Compounds of the class of 1-{1-[3-(10- phenothiaziny1)-propyl]-4-piperidyl}-2- benzimidazolinones, useful as neuroleptic agents.

8 Claims, No Drawings [(PHENOTHIAZINYL )PROPYL1-PIPERIDYL- BENZIMIDAZOLINONES CROSS-REFERENCE TO RELATED APPLICATIONS The application is a continuation-in-part of our copending application Ser. No. 333,855, filed Feb. 20, I973, now abandoned.

DESCRIPTION OF THE INVENTION This invention relates to a novel class of [(phenothiazinyl)-propyl]piperidyI-benzimidazolinones, in particular, those denoted as l-{l-[3-( phenothiazinyl)propyl]-4-piperidyl }-2- benzimidazolinones; which compounds may be structurally represented by the formula:

R s CH2 CH2 CH2 x HN I N I (I) and the therapeutically active non-toxic acid addition salts thereof, wherein R is a member selected from the group consisting of hydrogen, halo, trifluoromethyl and dimethylaminosulfonyl', Z and Z are selected from the group consisting of hydrogen, halo and methyl; R is selected from the group consisting of hydrogen and loweralkyl; and the dotted line indicates an optional double bond.

The Ioweralkyl referred to above is a straight or branch chained alkyl radicals having from I to 6 carbon atoms. As used herein, halo refers to bromo, fluoro, iodo and chloro, the latter being preferred. In the preferred embodiments, said R is in the 2-position of the phenothiazinyl moiety.

The subject compounds (I) are prepared by reacting an appropriate phenothiazine of formula (II), wherein R is as previously defined and X is a reactive ester of the corresponding alcohol, e.g., chloro, bromo, mesylate, tosylate, preferably chloro or bromo, with a compound of formula (III). This condensation reaction is 60 ing reactions are illustrated in the following scheme:

5 NCH -CH -CH conveniently conducted in an inert organic solvent such as, for example, an aromatic hydrocarbon, e.g., benzene, toluene, xylene and the like; a lower alkanol, e.g., methanol, ethanol, n-butanol and the like; a ketone, e.g., 4-methyl-2-pentanone, butanone, and the like; an ether, e.g., dioxane, diethyl ether and the like; dimethylformamide (DMF); nitrobenzene; and the like. The addition of an acid'acceptor, i.e., an appropriate base such as, for example, an alkali metal carbonate or bicarbonate, or an organic tertiary amine such as, for example, a trialkylamine, e.g., triethylamine, tributylamine and the like, or a heterocyclic amine. e.g., pyridine, quinoline and the like, may be utilized to bind the acid that is liberated during the course of the reaction. The amount of acid acceptor that may be employed is not critical, but, for optimum conditions, the theoretical number of moles of liberated acid can easily be calculated from the quantities of reactants employed and, thus, the corresponding amount of acid acceptor that need be employed can readily be determined. When X is halo, the presence of catalytic amounts of potassium iodide is also desirable. Elevated temperatures may be employed to enhance the rate of rsaqtiontpw (III) An alternative method for the preparation of the compounds of formula (I) consists in the quaternization of compounds of formula wherein n is l or 2, by means of compounds of formula (II) followed by dequaternization of the so-obtained compounds (IV,) by known methodologies. When n equals I, e.g., catalytic debenzylation may be effected; when n equals 2 dequaternization may be carried out, for instance, by treatment of the quaternary ammonium salt with potassium tertiary butylate. The forego- Q I i l V s -CH2CH2-CH2-NC N-R R Q z z' Yet another method for the preparation of the compounds (I) consists in starting from a compound (V), reducing the nitro-group thereof by known methods, for example, by catalytic hydrogenation using nobel metal catalysts or by reducing agents, such as, lithium aluminum hydride and the like, in a suitable organic solvent and then effecting ring closure of the obtained compound (VI) to build up the benzimidazolinonenucleus using appropriate cyclizing agents, such as urea, phosgene and the like. The compounds (l-a) thus-prepared, may be converted to the compounds (lb) by known alkylation methods, e.g., using trimethylanilinium bromide in the presence of sodium amide in dry toluene. The above reaction-sequence may be illustrated by the following scheme:

cH CH2 c11 @NH R Z N-CHZ-CHZ-CHZ-QNH N3 I R ,7 T Z Z 2 1 N H -CH -CH -CH I (La) HR Z 0 ll N 1k 5 CH2-CHZ-CH2-N -a The synthesis of compounds (I) may also be achieved by acylating compounds of formula (III) with a suitable acyl halide of formula (VII) preferably the chloride, and further reducing the amide of formula (Vlll) with an appropriate reducing agent, such as, lithium aluminum hydride. The above reaction sequence may be illustrated as follows:

-CH -CH X (111) (VIII) reducing agent ------9' cyclizing agent alkylating agent glycolic, lactic, pyruvic, malonic, succinic, maleic, fu-

maric, malic, tartaric, citric, benzoic, cinnamic, mandelic, methanesulfonic, ethanesulfonic, benzenesulfonic, p-toluenesulfonic, cyclohexanesulfamic, salicylic, p-aminosalicylic and the like acids. Conversely, the salt form can be converted by treatment with alkali into the free base form.

The compounds of formula (I) and the therapeutically active acid addition salts thereof have been found to possess central nervous system (CNS) depressant activity similar to the neuroleptic activity of butyrophenones, for example, haloperidol (see US. Pat. No. 3,438,991), and of certain benzimidazolinones, e.g., pimozide (see U.S. Pat. No. 3,196,157) and of the 4-aryl-4-hydroxypiperidines in U.S. Pat. No. 3575990. Although the subject compounds are qualitatively similar in neuroleptic activity to haloperidol, they differ significantly from the latter in their longer duration of action, similar to said pimozide and to said 4-aryl-4-hydroxypiperidines.

Neuroleptic drugs are known to block apomorphineinduced vomiting in dogs. In the anti-apomorphine test [see "Method 1" in .lanssen. P.A.J. et al.. Arzneim- Forsch. 15. 1196 (1965)]. the compound to be tested is given orally followed at different time intervals there after by the standard dose of apomorphine (0.31 mg/kg s.c.) which will induce vomiting in untreated dogs. Anti-apomorphine activity is demonstrated with the compounds (1) and salts thereof at oral dose levels as low as 0.005 mg/kg and at ED values of about 0.02-l.0 mg/kg orally. The ED value (in mg/kg) is the oral dose level of the tested compound protecting 50% of the animals from emesis. In Table 1, the ED values and the long duration of activity of the most preferred compounds described herein are given.

Another characterization of neuroleptic drugs is their ability to antagonize amphetamine-induced CNS- stimulation. 1n the amphetamine antagonism test, male Wistar rats are pretreated with an oral dose of the compound to be tested and challenged one hour thereafter with a standard dose of amphetamine (5 mg/kg i.v.). ln untreated animals, the standard dose of amphetamine will induce typical CNS-stimulation, e.g., agitation and I stereotyped chewing. These phenomena are antagonized by neuroleptic drugs, and, with the subject compounds, such antagonism is observed at oral dose levels of from about 0.05 to about 5.0 mg/kg. The data in Table 1 show the oral dose levels at which the most preferred compounds described herein protect the rats against the amphetamine-induced agitation and chewmg.

lt is understood that the compounds in Table l are not listed for purposes of limiting the invention thereto,

but only to exemplify the useful properties of all the compounds within the scope of formula (1), including the therapeutically active acid addition salts thereof.

The following examples are intended to illustrate, but

not to limit, the scope of the present invention. Unless otherwise stated, all parts are by weight.

EXAMPLE 1 EXAMPLE 11 A mixture of 1.8 parts of l0-(3-chloropropyl)-2- (a,a,a-trifluoromethyl)phenothiazine, 1.09 parts of 1- (4-piperidyl)-2-benzimidazolinone, 0.8 parts of anhydrous sodium carbonate, 0.2 parts of potassium iodide and 7.5 parts of dimethylformamide is stirred for hours while heating at 105C in an oil-bath. The reaction mixture is filtered and the filtrate is diluted with water. The precipitated product is filtered off and recrystallized from ethyl acetate, yielding l-[l'{3-[2- piperidyl]-2-benzimidazolinone; mp. 212.lC.

EXAMPLE v 111 A mixture of 1.23 parts of l0-(3-chloropropyl)-2- chlorophenothiazine, 1.09 parts of 1-(4-piperidyl)-2- benzimidazolinone, 0.8 parts of anhydrous sodium carbonate, 0.1 parts of. potassium iodide and 7.5 parts of dimethylformamide is stirred for 24 hours in an oil-bath at C. The reaction mixture is cooled, filtered over hyflo and the filtrate is diluted with water. The precipitated product is filtered off, washed with water, dried and taken up in ethyl acetate: the product is allowed to crystallize. It is filtered off and recrystallized twice: first from 2-propanol and then from boiling chloroform and an excess of acetone, yielding l- {l -[3-(2-chloro-l0- phenothiazinyl)propyl -4-piperidyl l-2- benzimidazolinone; mp. 2l6.2C (deo).

EXAMPLE 1V Each of the products obtained in the preceding examples is respectively treated with ethanolicl-lCl in the standard manner to produce the corresponding hydrochloride acid addition salt. ln turn, each of the latter salts is respectively treated with alkali (cg. aqueous NaOH) to yield the product in base form.

EXAMPLE V A mixture of 1.72 parts of l0-(3-chloropropyl)-2- (trifluoromethyl)-IOH-phenothiazine, 1.26 parts of 5- chloro-1-(4-piperidyl)-2-benzimidazolinone, 0.8 parts of sodium carbonate, 0.2 parts of potassium iodide and 7.5 parts of N,N-dimethylformamide is stirred and heated at 95C for 20 hours. The reaction mixture is cooled and filtered over hyflo. Upon the addition of water to the filtrate, the product is precipitated. It is filtered off and crystallized twice: first from boiling ethylacetate and then from 2propanol, yielding, after drying, 5-chloro-l,3-dihydro-l [1-l3-[2 (trifluoromethyl)- l ()H-phenothiazinl 0-yllpropyl }-4- piperidinyl] 2H-benzimidazol-2-onc; mp. 177.6C.

EXAMPLE v1 EXAMPLE VI] A mixture of 1.8 parts of l-(3-chloropropyl)2- (a,a,a-trifluoromethyl)phenothiazine, 1.08 parts of l-( l2,3,6-tetrahydro-4-pyridyl)-2-benzimidazolinone. 0.8 parts of sodium carbonate, a few crystals of potassium iodide and 7.5 parts of dimethylformamide is stirred for 20 hours at l 10C. The reaction mixture is cooled, filtered and upon the addition of water to the filtrate. the product is precipitated. It is filtered off and purified by column-chromatography, using a mixture of chloroform and 10% of methanol. The pure fractions are collected and the solvent is evaporated. The residue is converted into the cyclohexylsulfamate salt in acetone, yielding, after drying in vacuo at 50C, 1- {l ,2,3,6-tetrahydro-1-l 3-(2 trifluoromethyl-l0- phenothiazinyl)- propyll-4-pyridyl} -2-benzimidazolinone cyclohexanesulfamate; mp. l98275C(dec.).

EXAMPLE Vlll for 18 hours, l-[l-{3-[2-(dimethylaminosulfonyl)-10- phenothiazinyllpropyl 4-piperidyl]-2-benzimidazolinone; mp. 234,2C.

We claim:

1. A chemical compound selected from the group consisting of a l(phenothiazinyl)propyl]piperidylbenzimidazolinone having the formula:

and theitherapeutically active acid addition salts thereof, wherein R is a member selected from the group consisting of hydrogen, halo, trifluoromethyl and dimethylaminosulfonyl; Z and Z are selected from the group consisting of hydrogen, halo and methyl; R is selected from the group consisting of hydrogen and loweralkyl; and the dotted line indicates an optional double bond.

2. A chemical compound selected from the group consisting of a [(phenothiazinyl)propyllpiperidylbenzimidazolinone having the formula:

and the therapeutically active acid addition salts thereof, wherein R is a member selected from the group consisting of hydrogen halo, trifluoromethyl and dimethylaminosulfonyl;

Z and Z are selected from the group consisting of hydrogen, halo and methyl;

R is selected from the group consisting of hydrogen and loweralkyl; and

the dotted line indicates an optional double bond.

3. 1-{l-[3-(10-Phenothiazinyl)propyll-4-piperidyll- 2-benzimidazolinone.

4. 1-[l-l3-[2-(a,a,a-Trifluoromethyl)-10- phenothiazinyllpropyll-4-piperidyl]-2-benzimidazolinone.

5. l-{l-[3-(2-Chloro-10'phenothiazinyl)propyl]-4 piperidyl l-2-benzimidazolinone.

6. 5-Chloro-l,3-dihydro-l-[ l-{3[2- (trifluoromethyl)- 10H-phenothiazin-10-yl]propyll-4-piperidinyl]-2H- benzimidazol-Z-one.

7. l-{l,2,3,6-Tetrahyro-1-[3-(2-trifluoromethyllO-phenothiazinyl)propyl]-4pyridyll2- benzimidazolinone cyclohexanesulfamate.

8. 1-[l-{3-[2-(Dimethylaminosulfonyl)-10- phenothiazinyllpropyl}4-piperidyl]-2-benzimidazolin0ne. 

1. A CHEMICAL COMPOUND SELECTED FROM THE GROUP CONSISTING OF A ((PHENOTHIAZINYL)PROPYL)PIPERIDYL-BENIZIMIDAZOLINONE HAVING THE FORMULA
 2. A chemical compound selected from the group consisting of a ((phenothiazinyl)propyl)piperidyl-benzimidazolinone having the formula:
 3. 1-(1-(3-(10-Phenothiazinyl)propyl)-4-piperidyl)-2-benzimidazolinone.
 4. 1-(1-(3-(2-( Alpha , Alpha , Alpha -Trifluoromethyl)-10-phenothiazinyl)-propyl)-4-piperidyl)-2 -benzimidazolinone.
 5. 1-(1-(3-(2-Chloro-10-phenothiazinyl)propyl)-4-piperidyl)-2 -benzimidazolinone.
 6. 5-Chloro-1,3-dihydro-1-(1-(3-(2-(trifluoromethyl)-10H-phenothiazin-10 -yl)propyl)-4-piperidinyl)-2H-benzimidazol-2-one.
 7. 1-(1,2,3,6-Tetrahyro-1-(3-(2-trifluoromethyl-10-phenothiazinyl)propyl)-4 -pyridyl)-2-benzimidazolinone cyclohexanesulfamate.
 8. 1-(1-(3-(2-(Dimethylaminosulfonyl)-10-phenothiazinyl)-propyl)-4-piperidyl)-2-benzimidazolinone. 